SG11201408254UA - N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products - Google Patents
N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal productsInfo
- Publication number
- SG11201408254UA SG11201408254UA SG11201408254UA SG11201408254UA SG11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA SG 11201408254U A SG11201408254U A SG 11201408254UA
- Authority
- SG
- Singapore
- Prior art keywords
- berlin
- international
- str
- arylcarboxamides
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/001247 A1 (51) International Patent Classification: C07D 215/233 (2006.01) A61K31/47 (2006.01) C07D 401/12 (2006.01) A61K31/4709 (2006.01) C07D 413/12 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/063118 24 June 2013 (24.06.2013) English (30) Priority Data: 12004764.2 26 June 2012 (26.06.2012) English EP (71) Applicant: BAYER PHARMA AKTIENGESELL- SCHAFT [DE/DE]; Miillerstrasse 178, 13353 Berlin (DE). (72) Inventors: NGUYEN, Duy; Heinrich-Heine-StraBe 27, 10179 Berlin (DE). KUNZER, Hermann; Turiner Str. 4, 13347 Berlin (DE). FAUS GIMENEZ, Hortensia; Star- garder Str. 74 Quergebaude, 10437 Berlin (DE). BADER, Benjamin; Hillmannstr. 14, 13467 Berlin (DE). KOHR, Silke; Feuerdornweg 7, 14513 Teltow (DE). FRITSCH, Martin; Elisabeth-Selbert-Str. 27, 12355 Berlin (DE). (74) Agent: BIP PATENTS; c/o Bayer Intellectual Property GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) l> •t CJ i-H o o o CJ (54) Title: N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products (57) Abstract: The invention relates to N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, intermediates and methods for their production, use thereof for treating and/or preventing diseases and use thereof for producing medicinal products and use thereof for treating and/or preventing diseases, especially of hyperproliferative diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 | ||
| PCT/EP2013/063118 WO2014001247A1 (en) | 2012-06-26 | 2013-06-24 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408254UA true SG11201408254UA (en) | 2015-01-29 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408254UA SG11201408254UA (en) | 2012-06-26 | 2013-06-24 | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
Country Status (41)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2945819A1 (en) * | 2014-04-22 | 2015-10-29 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| AR102537A1 (en) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | IMMUNOMODULATING AGENTS |
| TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
| JP2019516687A (en) * | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Indoleamine 2,3-dioxygenase inhibitors and methods of use thereof |
| US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CA2413579A1 (en) | 2000-06-23 | 2002-01-03 | Eli Lilly And Company | Methods and compounds for inhibiting mrp1 |
| CN100415720C (en) | 2001-06-22 | 2008-09-03 | 麒麟医药株式会社 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same |
| AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| JP2006515014A (en) | 2003-01-30 | 2006-05-18 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 2,4-Diaminopyrimidine derivatives useful as inhibitors of PKC-θ |
| SE0302573D0 (en) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005094251A2 (en) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | M3muscarinic acetylcholine receptor antagonists |
| SE0401342D0 (en) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (en) | 2004-05-27 | 2005-12-15 | Jack Saffron | Feeding dish to prevent pest infestation |
| CA2586446A1 (en) | 2004-11-09 | 2006-05-18 | Smithkline Beecham Corporation | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| WO2007091694A1 (en) | 2006-02-06 | 2007-08-16 | Showa Denko K.K. | Whitening dermatological preparations |
| CN101528702A (en) | 2006-06-08 | 2009-09-09 | 阿雷生物药品公司 | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (en) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Polycyclic molecular compounds |
| EP2188277B1 (en) | 2007-08-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Quinazolinedione chymase inhibitors |
| CA2703635C (en) * | 2007-10-26 | 2017-06-27 | Michael E. Jung | Diarylhydantoin compounds as androgen receptor modulators |
| JP5699075B2 (en) | 2008-05-14 | 2015-04-08 | アムジエン・インコーポレーテツド | Combinations of VEGF (R) inhibitors and hepatocyte growth factor (C-MET) inhibitors for the treatment of cancer |
| AU2009300328A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| AP3409A (en) | 2009-07-21 | 2015-08-31 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| CA2773615A1 (en) | 2009-09-11 | 2011-03-17 | Arwed Cleve | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
-
2013
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 SI SI201330440A patent/SI2864291T1/en unknown
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/en unknown
- 2013-06-24 US US14/408,876 patent/US9428460B2/en active Active
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/en active Application Filing
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/en unknown
- 2013-06-24 EA EA201500039A patent/EA028063B1/en not_active IP Right Cessation
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/en active Active
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/en unknown
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/en not_active Application Discontinuation
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 PT PT137313250T patent/PT2864291T/en unknown
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/en active IP Right Grant
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/en not_active Application Discontinuation
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/en active Active
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/en active
- 2013-06-24 MA MA37700A patent/MA37700B1/en unknown
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 RS RS20161149A patent/RS55500B1/en unknown
- 2013-06-24 UA UAA201500561A patent/UA115447C2/en unknown
- 2013-06-24 CA CA2877786A patent/CA2877786C/en not_active Expired - Fee Related
- 2013-06-24 PL PL13731325T patent/PL2864291T3/en unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/en not_active Expired - Fee Related
- 2013-06-26 TW TW102122775A patent/TWI600646B/en not_active IP Right Cessation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/en unknown
- 2013-06-26 UY UY0001034881A patent/UY34881A/en not_active Application Discontinuation
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/en unknown
- 2014-12-18 CR CR20140593A patent/CR20140593A/en unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/en unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/en unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/en unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/en unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869B1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/en unknown
-
2015
- 2015-07-21 HK HK15106940.1A patent/HK1206346A1/en not_active IP Right Cessation
-
2016
- 2016-12-19 HR HRP20161745TT patent/HRP20161745T1/en unknown
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807426WA (en) | Immunomodulators | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201803882PA (en) | Oat-based product and process of manufacture | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201408254UA (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| SG11201408502XA (en) | Method of purifying an antibody | |
| SG11201407679PA (en) | Manufacture of degarelix |